Answers are grounded in this paper and cite their sources.
sponsorship: this work was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC; Milano, Italy), Special Program Molecular Clinical Oncology 5x1000 to AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) project #1005. A complete list of AGIMM investigators is available at http://www.progettoagimm.it. P.G. also received funding by AIRC IG2014-15967 and by the Ministero della Salute (project code GR-2011-02352109). The Varese group was also supported by grants of the Fondazione Regionale Ricerca Biomedica, Milan, Italy [FRRB project no. 2015-0042, Genomic profiling of rare hematologic malignancies, development of personalized medicine strategies, and their implementation into the Rete Ematologica Lombarda (REL) clinical network], by Fondazione Matarelli (Milano, Italy), Fondazione Rusconi (Varese, Italy) and AIL Varese ONLUS. T.G. acknowledges research funding from the Department of Medicine and Surgery, University of Insubria. R.T.S. was supported in part by the Cancer Research and Treatment Fund, Inc., New York, NY. (Associazione Italiana per la Ricerca sul Cancro (AIRC; Milano, Italy), Special Program Molecular Clinical Oncology|5x1000, Associazione Italiana per la Ricerca sul Cancro (AIRC; Milano, Italy), Special Program Molecular Clinical Oncology|1005, AIRC|IG2014-15967, Ministero della Salute|GR-2011-02352109, Fondazione Regionale Ricerca Biomedica, Milan, Italy [FRRB project]|2015-0042, Fondazione Matarelli (Milano, Italy), Fondazione Rusconi (Varese, Italy), AIL Varese ONLUS, Department of Medicine and Surgery, University of Insubria, Cancer Research and Treatment Fund, Inc., New York, NY)
No takes yet. Share an insight, caveat, or question.
Mora et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: